Olink Proteomics Inc.

Olink Proteomics Inc., a foreign-owned for-profit biotechnology company based in Waltham, Massachusetts, operates as a wholly owned subsidiary of Thermo Fisher Scientific Inc. and supplies advanced proteomics instruments, reagent kits, and protein biomarker analysis services to federal health agencies and defense research programs as a prime contractor on all fifty-four recent awards—competing exclusively in full-and-open, non-set-aside procurements across the federal biomedical research establishment.

Olink's federal footprint centers on proximity extension assay (PEA) platforms and high-multiplex protein measurement technologies. The company supplies proprietary instrument systems—chiefly the Olink Signature Q100 and Olink Explore HT platforms—alongside complementary reagent kits (Target and Explore panel variants), integrated fluidic circuits, and analysis services for proteomics research. Representative prime work includes a $249,732.24 firm fixed-price contract from the National Institute of Allergy and Infectious Diseases (September 2025–September 2026) for a PCR-based proximity extension assay system to measure inflammatory cytokine and chemokine proteins in influenza and SARS-CoV-2 research samples; a $206,861.31 contract from the National Institute of Neurological Disorders and Stroke (May 2026–May 2027) for genome sequencing of DNA samples from patients with neurodegenerative diseases; and a $187,601.80 National Cancer Institute order (May 2023) for an Olink Signature Q100 starter kit and reagents to support cancer research. A significant subset of awards involve service agreements for analysis work—for example, a $106,675.00 Food and Drug Administration contract (July 2025) for quantitative proteomics measurement of over 5,000 proteins in 100 cancer patient plasma samples to assess cardiotoxicity biomarkers.

The Defense Health Agency anchors Olink's dollar concentration. A single-award indefinite delivery contract valued at $3.4 million (May 2023–May 2028) supplies Olink Target reagent kits to the Walter Reed Army Institute of Research's Medical Readiness Systems Biology Branch, with one task order ($37 thousand) issued to date. However, award count concentration tracks with the National Institutes of Health ecosystem. The top five customer agencies account for 67 percent of recent awards by count, led by the National Institute on Aging (10 awards, $1.1 million combined potential value), the NIH Clinical Center (9 awards, $307 thousand), the National Cancer Institute (7 awards, $490 thousand), the Food and Drug Administration (6 awards, $636 thousand), and the National Heart Lung and Blood Institute (4 awards, $211 thousand). When ranked by potential value, the Defense Health Agency IDC dominates (42 percent of total dollar potential), followed by the National Institute on Aging and FDA. Activity has held steady at nine to thirteen awards annually over the past four years; nine awards carrying $922 thousand in combined potential value complete within the next twenty-four months and face recompete exposure.

Award distribution reflects Olink's natural NAICS footprint: Analytical Laboratory Instrument Manufacturing (15 awards), Testing Laboratories and Services (12 awards), In-Vitro Diagnostic Substance Manufacturing (8 awards), and Biological Product Manufacturing (7 awards). Purchase orders dominate the vehicle mix, with no parent IDIQs or GWACs in the source data; the single task order reported sits on an IDC with the Defense Health Agency. All fifty-four awards are prime contracts with no subcontractor engagement recorded, and all are issued without set-aside designations—Olink competes and wins exclusively in full-and-open federal health and research procurements. The source identifies no federal grant work, no sub-awards, and no involvement in teaming arrangements. Performance takes place predominantly in Waltham, Massachusetts (Olink's headquarters location), with some work performed at customer sites such as Bethesda, Maryland (NIH facilities) and College Station, Texas (Forest Service).

The parent company, Thermo Fisher Scientific Inc., is a multinational life sciences corporation with substantial federal contracting experience across both civilian and defense agencies. Olink's positioning within this larger parent provides supply-chain stability and integration with Thermo Fisher's broader scientific-equipment and reagent distribution network, though the source does not indicate shared federal contract vehicles or significant teaming between the subsidiary and parent at the federal level.